Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07920289
PHASE1/PHASE2

Intravenously Administered PROMITIL Combined With Radiotherapy in Patients With Cisplatin-Ineligible Head and Neck Cancer Patients

Sponsor: Assuta Ashdod Hospital

View on ClinicalTrials.gov

Summary

This will be an open-label, single-arm, prospective study, in which patients requiring RT for locally and/or regionally advanced head and neck cancers will undergo a combination treatment comprised of intravenously delivered PROMITIL and standard-of-care radiotherapy (RT). The treatment regimen will involve administration of 3 PROMITIL doses, delivered at 21-day intervals, and a course of external beam radiotherapy (EBR), initiated 1-3 days after the first PROMITIL dose. EBR will consist of either standard daily fractionation (5 per week) of up to a total of 70 Gy at 2 Gy/fraction (7 weeks) or a hypofractionated regimen of up to 55 Gy at 2.75 Gy/fraction (HYPNO regimen; 4 weeks), per investigator's preference. PROMITIL will be given by intravenous infusion at a dose of 2 mg/kg body weight with a capped maximal dose of 150 mg. Five sentinel patients (the first five enrolled patients) will be treated with a dose of 1.8 mg/kg body weight for the purpose of conducting a safety analysis to determine tolerability of the dosing regimen prior to enrolling the remaining study patients. Treatment safety will be assessed on a weekly basis, as well as 4 weeks after the last RT treatment. Disease status will be reevaluated 28 days (±7 days) from the end of last radiation treatment by a direct clinical examination. PET CT or CT will be conducted 12 weeks (±7 days) from the end of RT treatment. Thereafter, PET CT and/or CT scans will be repeated every 6 months for the first 24 months, followed by yearly imaging. In addition, during the follow-up phase, the patient will be assessed by a radiation oncologist and/or ENT specialist every 3 months during the first year, every 4 months during the second and third years and every 6 months in years 4 and 5 of observation. A first interim analysis will be conducted 3 months after end of treatment to evaluate safety and response rate. A second interim analysis will be conducted 2 years after end of treatment to evaluate event-free survival (EFS) and delayed toxicities. Final analysis of long-term disease control and survival will be conducted after 5 years.

Official title: An Open-label, Phase IB/IIA Single-Arm Trial of Intravenously Administered Pegylated Liposomal Mitomycin C Lipid-based Prodrug (PROMITIL) in Combination With External Beam Radiotherapy in Patients With Cisplatin-Ineligible Head and Neck Cancer Patients ("LIPORAD- 2")

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

20

Start Date

2026-10-30

Completion Date

2033-05-30

Last Updated

2026-11-05

Healthy Volunteers

No

Interventions

DRUG

Addition of Promitil to External Beam Radiotherapy

The treatment regimen will involve administration of 3 PROMITIL doses, delivered at 21-day intervals, and a course of external beam radiotherapy (EBR), initiated 1-3 days after the first PROMITIL dose. EBR will consist of either standard daily fractionation (5 per week) of up to a total of 70 Gy at 2 Gy/fraction (7 weeks) or a hypofractionated regimen of up to 55 Gy at 2.75 Gy/fraction (HYPNO regimen; 4 weeks), per investigator's preference. PROMITIL will be given by intravenous infusion at a dose of 2 mg/kg body weight with a capped maximal dose of 150 mg. Five sentinel patients (the first five enrolled patients) will be treated with a dose of 1.8 mg/kg body weight for the purpose of conducting a safety analysis to determine tolerability of the dosing regimen prior to enrolling the remaining study patients.